These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1431348)

  • 1. Effectiveness of 6-month intermittent administration of natural human interferon-alpha against non-A non-B chronic hepatitis.
    Sata M; Atono Y; Nakano H; Morita Y; Hino T; Ide T; Yano Y; Noguchi S; Tokeshi S; Ono K
    Kansenshogaku Zasshi; 1992 Jun; 66(6):667-78. PubMed ID: 1431348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load.
    Arase Y; Suzuki F; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Kobayashi M; Sezaki H; Ikeda K; Kumada H
    Intervirology; 2004; 47(1):19-25. PubMed ID: 15044832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective administration methods and dosages of interferon therapy for chronic hepatitis C.
    Nomura H; Kimura Y; Tada H; Hisano C; Morita C; Okamoto O; Shiraishi G; Higashi M; Kashiwagi S
    Clin Ther; 1996; 18(4):671-9. PubMed ID: 8879895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
    Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers.
    Okazaki T; Yoshihara H; Suzuki K; Yamada Y; Tsujimura T; Kawano K; Yamada Y; Abe H
    Scand J Gastroenterol; 1994 Nov; 29(11):1039-43. PubMed ID: 7871371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two years versus six months of interferon therapy for chronic hepatitis C.
    Farrell GC
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):93S-98S. PubMed ID: 9011483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C with interferon-alpha: sustained absence of hepatitis C virus RNA from serum after four courses of therapy.
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S; Takahashi M
    J Int Med Res; 1995; 23(4):308-14. PubMed ID: 7589775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.
    Furusyo N; Hayashi J; Ohmiya M; Sawayama Y; Kawakami Y; Ariyama I; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 1999 Mar; 44(3):608-17. PubMed ID: 10080158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.
    Hwang SJ; Chan CY; Lu RH; Wu JC; Lee SD
    J Interferon Cytokine Res; 1995 Jul; 15(7):611-6. PubMed ID: 7553231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group.
    Shiratori Y; Kato N; Yokosuka O; Imazeki F; Hashimoto E; Hayashi N; Nakamura A; Asada M; Kuroda H; Tanaka N; Arakawa Y; Omata M
    Gastroenterology; 1997 Aug; 113(2):558-66. PubMed ID: 9247476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
    Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
    Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W; Graziadei I; Umlauft F; Datz C; Hackl F; Allinger S; Grünewald K; Patsch J
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
    Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
    Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection.
    Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
    Arch Virol; 1997; 142(3):535-44. PubMed ID: 9349299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study.
    Sangiovanni A; Morales R; Spinzi G; Rumi M; Casiraghi A; Ceriani R; Colombo E; Fossati M; Prada A; Tavani E; Minoli G
    Hepatology; 1998 Mar; 27(3):853-6. PubMed ID: 9500717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
    J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.